Short stature is one of the characteristic features of TS and it is considered the main problem to the patients and their relatives. Some therapeutic schemes to promote growth in these patients were tested in the last years. It is necessary to use specific growth charts in the follow up of these patients, since the growth differs considerably from normal standards. We have studied, retrospectively, 124 patients with TS. From these, 58 attained final height (FH) - cronological age > 14 years with bone age ≥ 16 years, or growth velocity ≤ 1cm/year. The most frequent cariotypes were 45,X (43,1%) and 45,X/46,XX (17,2%). The patients mean age was 20,2 years(±4,6 years) and only two of them were <16 years. The observed FH ranged between 130,5cm and 156,5cm ([horizontal bar over]x=141,7cm, SD=6,6cm), and eight (13,8%) of them attained FH≥ 150cm. The patients born before 1975 attained mean FH of 140,9cm (±6,4cm) while the patients born after 1975 attained mean FH of 143,7cm (±6,3cm). The patients who developed hypothyrodism attained mean FH of 143,0cm (±6,3cm). The FH of the different gorups was not statistically significant. The mean height (MH) of the mothers of 53 of the patients was 157,4cm (±7,9cm), the MH of 49 of the fathers was 167,1cm (±7,5cm) and the mean target height of 49 patients was 156,0cm (±6,1cm). In a study performed in São Paulo the women's MH was 159,9cm (±6,3cm) and the men's MH was 173,3cm(±7,3cm). Two of the patients received HGH, and their FH were 136,5cm(in association with oxandrolone) and 151,0cm. Two patients received oxandrolone, and their FH were 136,5cm (in association with HGH) and 140,6cm 41 of the patients received oestrogen: 16 received low dose - beginning at the minimal age of 10 years - and 25 received mean or high dose - beginning at 12 and 15 years, respectively.